Search

Your search keyword '"Suda, Kazuaki"' showing total 46 results
Start Over Author "Suda, Kazuaki"
46 results on '"Suda, Kazuaki"'

6. Supplementary Figure legend from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

Author

Akashi, Hidehiko, primary, Yachida, Nozomi, primary, Ueda, Haruka, primary, Yamaguchi, Manako, primary, Yamawaki, Kaoru, primary, Tamura, Ryo, primary, Suda, Kazuaki, primary, Ishiguro, Tatsuya, primary, Adachi, Sosuke, primary, Nagase, Yoshikazu, primary, Ueda, Yutaka, primary, Ueda, Masashi, primary, Abiko, Kaoru, primary, Kagabu, Masahiro, primary, Baba, Tsukasa, primary, Nakaoka, Hirofumi, primary, Enomoto, Takayuki, primary, Murai, Junko, primary, and Yoshihara, Kosuke, primary

Published
2024
Full Text
View/download PDF

7. Supplementary Table 3 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

Author

Akashi, Hidehiko, primary, Yachida, Nozomi, primary, Ueda, Haruka, primary, Yamaguchi, Manako, primary, Yamawaki, Kaoru, primary, Tamura, Ryo, primary, Suda, Kazuaki, primary, Ishiguro, Tatsuya, primary, Adachi, Sosuke, primary, Nagase, Yoshikazu, primary, Ueda, Yutaka, primary, Ueda, Masashi, primary, Abiko, Kaoru, primary, Kagabu, Masahiro, primary, Baba, Tsukasa, primary, Nakaoka, Hirofumi, primary, Enomoto, Takayuki, primary, Murai, Junko, primary, and Yoshihara, Kosuke, primary

Published
2024
Full Text
View/download PDF

8. Supplementary Table 7 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

Author

Akashi, Hidehiko, primary, Yachida, Nozomi, primary, Ueda, Haruka, primary, Yamaguchi, Manako, primary, Yamawaki, Kaoru, primary, Tamura, Ryo, primary, Suda, Kazuaki, primary, Ishiguro, Tatsuya, primary, Adachi, Sosuke, primary, Nagase, Yoshikazu, primary, Ueda, Yutaka, primary, Ueda, Masashi, primary, Abiko, Kaoru, primary, Kagabu, Masahiro, primary, Baba, Tsukasa, primary, Nakaoka, Hirofumi, primary, Enomoto, Takayuki, primary, Murai, Junko, primary, and Yoshihara, Kosuke, primary

Published
2024
Full Text
View/download PDF

9. Supplementary Table 8 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

Author

Akashi, Hidehiko, primary, Yachida, Nozomi, primary, Ueda, Haruka, primary, Yamaguchi, Manako, primary, Yamawaki, Kaoru, primary, Tamura, Ryo, primary, Suda, Kazuaki, primary, Ishiguro, Tatsuya, primary, Adachi, Sosuke, primary, Nagase, Yoshikazu, primary, Ueda, Yutaka, primary, Ueda, Masashi, primary, Abiko, Kaoru, primary, Kagabu, Masahiro, primary, Baba, Tsukasa, primary, Nakaoka, Hirofumi, primary, Enomoto, Takayuki, primary, Murai, Junko, primary, and Yoshihara, Kosuke, primary

Published
2024
Full Text
View/download PDF

10. Supplementary Table 6 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

Author

Akashi, Hidehiko, primary, Yachida, Nozomi, primary, Ueda, Haruka, primary, Yamaguchi, Manako, primary, Yamawaki, Kaoru, primary, Tamura, Ryo, primary, Suda, Kazuaki, primary, Ishiguro, Tatsuya, primary, Adachi, Sosuke, primary, Nagase, Yoshikazu, primary, Ueda, Yutaka, primary, Ueda, Masashi, primary, Abiko, Kaoru, primary, Kagabu, Masahiro, primary, Baba, Tsukasa, primary, Nakaoka, Hirofumi, primary, Enomoto, Takayuki, primary, Murai, Junko, primary, and Yoshihara, Kosuke, primary

Published
2024
Full Text
View/download PDF

11. Data from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

Author

Akashi, Hidehiko, primary, Yachida, Nozomi, primary, Ueda, Haruka, primary, Yamaguchi, Manako, primary, Yamawaki, Kaoru, primary, Tamura, Ryo, primary, Suda, Kazuaki, primary, Ishiguro, Tatsuya, primary, Adachi, Sosuke, primary, Nagase, Yoshikazu, primary, Ueda, Yutaka, primary, Ueda, Masashi, primary, Abiko, Kaoru, primary, Kagabu, Masahiro, primary, Baba, Tsukasa, primary, Nakaoka, Hirofumi, primary, Enomoto, Takayuki, primary, Murai, Junko, primary, and Yoshihara, Kosuke, primary

Published
2024
Full Text
View/download PDF

12. Supplementary Figure 2 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

Author

Akashi, Hidehiko, primary, Yachida, Nozomi, primary, Ueda, Haruka, primary, Yamaguchi, Manako, primary, Yamawaki, Kaoru, primary, Tamura, Ryo, primary, Suda, Kazuaki, primary, Ishiguro, Tatsuya, primary, Adachi, Sosuke, primary, Nagase, Yoshikazu, primary, Ueda, Yutaka, primary, Ueda, Masashi, primary, Abiko, Kaoru, primary, Kagabu, Masahiro, primary, Baba, Tsukasa, primary, Nakaoka, Hirofumi, primary, Enomoto, Takayuki, primary, Murai, Junko, primary, and Yoshihara, Kosuke, primary

Published
2024
Full Text
View/download PDF

13. Supplementary Table 9 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

Author

Akashi, Hidehiko, primary, Yachida, Nozomi, primary, Ueda, Haruka, primary, Yamaguchi, Manako, primary, Yamawaki, Kaoru, primary, Tamura, Ryo, primary, Suda, Kazuaki, primary, Ishiguro, Tatsuya, primary, Adachi, Sosuke, primary, Nagase, Yoshikazu, primary, Ueda, Yutaka, primary, Ueda, Masashi, primary, Abiko, Kaoru, primary, Kagabu, Masahiro, primary, Baba, Tsukasa, primary, Nakaoka, Hirofumi, primary, Enomoto, Takayuki, primary, Murai, Junko, primary, and Yoshihara, Kosuke, primary

Published
2024
Full Text
View/download PDF

14. Supplementary Table 4 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

Author

Akashi, Hidehiko, primary, Yachida, Nozomi, primary, Ueda, Haruka, primary, Yamaguchi, Manako, primary, Yamawaki, Kaoru, primary, Tamura, Ryo, primary, Suda, Kazuaki, primary, Ishiguro, Tatsuya, primary, Adachi, Sosuke, primary, Nagase, Yoshikazu, primary, Ueda, Yutaka, primary, Ueda, Masashi, primary, Abiko, Kaoru, primary, Kagabu, Masahiro, primary, Baba, Tsukasa, primary, Nakaoka, Hirofumi, primary, Enomoto, Takayuki, primary, Murai, Junko, primary, and Yoshihara, Kosuke, primary

Published
2024
Full Text
View/download PDF

15. Supplementary Table 5 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

Author

Akashi, Hidehiko, primary, Yachida, Nozomi, primary, Ueda, Haruka, primary, Yamaguchi, Manako, primary, Yamawaki, Kaoru, primary, Tamura, Ryo, primary, Suda, Kazuaki, primary, Ishiguro, Tatsuya, primary, Adachi, Sosuke, primary, Nagase, Yoshikazu, primary, Ueda, Yutaka, primary, Ueda, Masashi, primary, Abiko, Kaoru, primary, Kagabu, Masahiro, primary, Baba, Tsukasa, primary, Nakaoka, Hirofumi, primary, Enomoto, Takayuki, primary, Murai, Junko, primary, and Yoshihara, Kosuke, primary

Published
2024
Full Text
View/download PDF

16. Supplementary Table 1 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

Author

Akashi, Hidehiko, primary, Yachida, Nozomi, primary, Ueda, Haruka, primary, Yamaguchi, Manako, primary, Yamawaki, Kaoru, primary, Tamura, Ryo, primary, Suda, Kazuaki, primary, Ishiguro, Tatsuya, primary, Adachi, Sosuke, primary, Nagase, Yoshikazu, primary, Ueda, Yutaka, primary, Ueda, Masashi, primary, Abiko, Kaoru, primary, Kagabu, Masahiro, primary, Baba, Tsukasa, primary, Nakaoka, Hirofumi, primary, Enomoto, Takayuki, primary, Murai, Junko, primary, and Yoshihara, Kosuke, primary

Published
2024
Full Text
View/download PDF

17. Supplementary Figure 1 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

Author

Akashi, Hidehiko, primary, Yachida, Nozomi, primary, Ueda, Haruka, primary, Yamaguchi, Manako, primary, Yamawaki, Kaoru, primary, Tamura, Ryo, primary, Suda, Kazuaki, primary, Ishiguro, Tatsuya, primary, Adachi, Sosuke, primary, Nagase, Yoshikazu, primary, Ueda, Yutaka, primary, Ueda, Masashi, primary, Abiko, Kaoru, primary, Kagabu, Masahiro, primary, Baba, Tsukasa, primary, Nakaoka, Hirofumi, primary, Enomoto, Takayuki, primary, Murai, Junko, primary, and Yoshihara, Kosuke, primary

Published
2024
Full Text
View/download PDF

18. Supplementary Table 2 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

Author

Akashi, Hidehiko, primary, Yachida, Nozomi, primary, Ueda, Haruka, primary, Yamaguchi, Manako, primary, Yamawaki, Kaoru, primary, Tamura, Ryo, primary, Suda, Kazuaki, primary, Ishiguro, Tatsuya, primary, Adachi, Sosuke, primary, Nagase, Yoshikazu, primary, Ueda, Yutaka, primary, Ueda, Masashi, primary, Abiko, Kaoru, primary, Kagabu, Masahiro, primary, Baba, Tsukasa, primary, Nakaoka, Hirofumi, primary, Enomoto, Takayuki, primary, Murai, Junko, primary, and Yoshihara, Kosuke, primary

Published
2024
Full Text
View/download PDF

19. XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary

Author

Tamura, Ryo, Yoshihara, Kosuke, Nakaoka, Hirofumi, Yachida, Nozomi, Yamaguchi, Manako, Suda, Kazuaki, Ishiguro, Tatsuya, Nishino, Koji, Ichikawa, Hiroshi, Homma, Keiichi, Kikuchi, Akira, Ueda, Yutaka, Takei, Yuji, Fujiwara, Hiroyuki, Motoyama, Teiichi, Okuda, Shujiro, Wakai, Toshifumi, Inoue, Ituro, and Enomoto, Takayuki

Published
2020
Full Text
View/download PDF

20. Endometrial Cancer with and without Endometriosis: Clinicopathological Differences

Author

Minamikawa, Takahiro, primary, Yachida, Nozomi, additional, Takahashi, Kotaro, additional, Saito, Kyota, additional, Sekizuka, Tomoyuki, additional, Akashi, Hidehiko, additional, Suzuki, Miho, additional, Mori, Yutaro, additional, Yamawaki, Kaoru, additional, Suda, Kazuaki, additional, Tamura, Ryo, additional, Adachi, Sosuke, additional, and Yoshihara, Kosuke, additional

Published
2023
Full Text
View/download PDF

21. SLFN11 is a BRCA independent biomarker for the response to platinum-based chemotherapy in high-grade serous ovarian cancer and clear cell ovarian carcinoma

Author

Akashi, Hidehiko, primary, Yachida, Nozomi, additional, Ueda, Haruka, additional, Yamaguchi, Manako, additional, Yamawaki, Kaoru, additional, Tamura, Ryo, additional, Suda, Kazuaki, additional, Ishiguro, Tatsuya, additional, Adachi, Sosuke, additional, Nagase, Yoshikazu, additional, Ueda, Yutaka, additional, Ueda, Masashi, additional, Abiko, Kaoru, additional, Kagabu, Masahiro, additional, Baba, Tsukasa, additional, Nakaoka, Hirofumi, additional, Enomoto, Takayuki, additional, Murai, Junko, additional, and Yoshihara, Kosuke, additional

Published
2023
Full Text
View/download PDF

25. Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions

Author

Tamura, Ryo, Yoshihara, Kosuke, Saito, Tetsuya, Ishimura, Ryosuke, Martínez-Ledesma, Juan Emmanuel, Xin, Hu, Ishiguro, Tatsuya, Mori, Yutaro, Yamawaki, Kaoru, Suda, Kazuaki, Sato, Seiya, Itamochi, Hiroaki, Motoyama, Teiichi, Aoki, Yoichi, Okuda, Shujiro, Casingal, Cristine R., Nakaoka, Hirofumi, Inoue, Ituro, Verhaak, Roel G. W., Komatsu, Masaaki, and Enomoto, Takayuki

Published
2018
Full Text
View/download PDF

27. Proposing a molecular classification associated with hypercoagulation in ovarian clear cell carcinoma

Author

Tamura, Ryo, primary, Yoshihara, Kosuke, additional, Matsuo, Koji, additional, Yachida, Nozomi, additional, Miyoshi, Ai, additional, Takahashi, Kotaro, additional, Sugino, Kentaro, additional, Yamaguchi, Manako, additional, Mori, Yutaro, additional, Suda, Kazuaki, additional, Ishiguro, Tatsuya, additional, Okuda, Shujiro, additional, Motoyama, Teiichi, additional, Nakaoka, Hirofumi, additional, Kikuchi, Akira, additional, Ueda, Yutaka, additional, Inoue, Ituro, additional, and Enomoto, Takayuki, additional

Published
2021
Full Text
View/download PDF

29. Biological significance of KRAS mutant allele expression in ovarian endometriosis

Author

Yachida, Nozomi, primary, Yoshihara, Kosuke, additional, Suda, Kazuaki, additional, Nakaoka, Hirofumi, additional, Ueda, Haruka, additional, Sugino, Kentaro, additional, Yamaguchi, Manako, additional, Mori, Yutaro, additional, Yamawaki, Kaoru, additional, Tamura, Ryo, additional, Ishiguro, Tatsuya, additional, Kase, Hiroaki, additional, Motoyama, Teiichi, additional, and Enomoto, Takayuki, additional

Published
2021
Full Text
View/download PDF

31. Establishment of in vitro 3D spheroid cell cultivation from human gynecologic cancer tissues

Author

Ueda, Haruka, primary, Mori, Yutaro, additional, Yamawaki, Kaoru, additional, Ishiguro, Tatsuya, additional, Ohata, Hirokazu, additional, Sato, Ai, additional, Sugino, Kentaro, additional, Yachida, Nozomi, additional, Yamaguchi, Manako, additional, Suda, Kazuaki, additional, Tamura, Ryo, additional, Yoshihara, Kosuke, additional, Okamoto, Koji, additional, and Enomoto, Takayuki, additional

Published
2021
Full Text
View/download PDF

33. Three-dimensional understanding of the morphological complexity of the human uterine endometrium

Author

Yamaguchi, Manako, primary, Yoshihara, Kosuke, additional, Suda, Kazuaki, additional, Nakaoka, Hirofumi, additional, Yachida, Nozomi, additional, Ueda, Haruka, additional, Sugino, Kentaro, additional, Mori, Yutaro, additional, Yamawaki, Kaoru, additional, Tamura, Ryo, additional, Ishiguro, Tatsuya, additional, Motoyama, Teiichi, additional, Watanabe, Yu, additional, Okuda, Shujiro, additional, Tainaka, Kazuki, additional, and Enomoto, Takayuki, additional

Published
2020
Full Text
View/download PDF

37. Clonal Expansion and Diversification of Cancer-Associated Mutations in Endometriosis and Normal Endometrium

Author

Suda, Kazuaki, primary, Nakaoka, Hirofumi, additional, Yoshihara, Kosuke, additional, Ishiguro, Tatsuya, additional, Tamura, Ryo, additional, Mori, Yutaro, additional, Yamawaki, Kaoru, additional, Adachi, Sosuke, additional, Takahashi, Tomoko, additional, Kase, Hiroaki, additional, Tanaka, Kenichi, additional, Yamamoto, Tadashi, additional, Motoyama, Teiichi, additional, Inoue, Ituro, additional, and Enomoto, Takayuki, additional

Published
2018
Full Text
View/download PDF

38. Abstract 529: The significance of activated PI3K/AKT pathway inFGFR3-TACC3fusion positive cervical cancer

Author

Tamura, Ryo, primary, Yoshihara, Kosuke, additional, Saito, Tetsuya, additional, Ishimura, Ryosuke, additional, Martínez-Ledesma, Emmanuel, additional, Mori, Yutaro, additional, Yamawaki, Kaoru, additional, Suda, Kazuaki, additional, Ishiguro, Tatsuya, additional, Aoki, Yoichi, additional, Sato, Seiya, additional, Itamochi, Hiroaki, additional, Komatsu, Masaaki, additional, Verhaak, Roeland, additional, and Enomoto, Takayuki, additional

Published
2017
Full Text
View/download PDF

39. Sox2-dependent inhibition of p21 is associated with poor prognosis of endometrial cancer

Author

Yamawaki, Kaoru, primary, Ishiguro, Tatsuya, additional, Mori, Yutaro, additional, Yoshihara, Kosuke, additional, Suda, Kazuaki, additional, Tamura, Ryo, additional, Yamaguchi, Masayuki, additional, Sekine, Masayuki, additional, Kashima, Katsunori, additional, Higuchi, Masaya, additional, Fujii, Masahiro, additional, Okamoto, Koji, additional, and Enomoto, Takayuki, additional

Published
2017
Full Text
View/download PDF

42. Novel kinase fusion transcripts found in endometrial cancer

Author

Tamura, Ryo, primary, Yoshihara, Kosuke, additional, Yamawaki, Kaoru, additional, Suda, Kazuaki, additional, Ishiguro, Tatsuya, additional, Adachi, Sosuke, additional, Okuda, Shujiro, additional, Inoue, Ituro, additional, Verhaak, Roel G. W., additional, and Enomoto, Takayuki, additional

Published
2015
Full Text
View/download PDF

43. Laparoscopic Surgery for Patients with Early Stage Endometrial Cancer

Author

Adachi, Sosuke, primary, Yahata, Tetsuro, additional, Kudo, Risa, additional, Yamagishi, Yoko, additional, Yamawaki, Kaoru, additional, Suda, Kazuaki, additional, Tamura, Ryo, additional, Chihara, Makoto, additional, Ishiguro, Tatsuya, additional, Minamikawa, Takahiro, additional, Banzai, Chiaki, additional, Nishino, Koji, additional, Nishikawa, Nobumichi, additional, Kashima, Katsunori, additional, and Enomoto, Takayuki, additional

Published
2013
Full Text
View/download PDF

44. Establishment of in vitro3D spheroid cell cultivation from human gynecologic cancer tissues

Author

Ueda, Haruka, Mori, Yutaro, Yamawaki, Kaoru, Ishiguro, Tatsuya, Ohata, Hirokazu, Sato, Ai, Sugino, Kentaro, Yachida, Nozomi, Yamaguchi, Manako, Suda, Kazuaki, Tamura, Ryo, Yoshihara, Kosuke, Okamoto, Koji, and Enomoto, Takayuki

Abstract

Advanced-stage gynecologic cancer remains a life-threatening disease. Here, we present a protocol for establishment of stable in vitro3D spheroid cells derived from human uterine endometrial and ovarian cancer tissues. The tumor-derived spheroid cells have cancer stem cell-related characteristics, including tumorigenesis, and can be used for biological and biochemical analyses and drug efficacy assays. Because these cells possess the biological characteristics of original human tumors, spheroid cells and spheroid-derived xenografts will have applications in personalized medicine in the future.

Published
2021
Full Text
View/download PDF

45. Reevaluating hybrid neurofibroma/schwannoma: Predominance of schwannoma features despite CD34 positivity and initial neurofibroma diagnosis.

Author

Katsumi T, Hayashi R, Takei S, Ansai O, Takatsuka S, Takenouchi T, Saito K, Suda K, Yoshihara K, Nagai T, Okuda S, Fukumoto T, Ansai SI, Nakamura A, Katsuumi K, Ariizumi T, Ogose A, Kawashima H, and Abe R

Subjects
Humans, Female, Male, Adult, Middle Aged, Neurofibromatoses, Antigens, CD34 analysis, Antigens, CD34 metabolism, Neurilemmoma diagnosis, Neurilemmoma pathology, Neurofibroma pathology, Neurofibroma diagnosis, Neurofibroma metabolism, Skin Neoplasms pathology, Skin Neoplasms diagnosis, Skin Neoplasms metabolism
Abstract

Schwannomas consist of both high-cellularity regions (Antoni A area) and hypocellular regions (Antoni B area) in histopathological findings. Neurofibromas characteristically consist of CD34 positive spindle cells with thin, wavy, nuclei and wavy collagen bands. Previous reports have described segments of schwannomas with neurofibroma features as hybrid tumors, although hybrid tumors were diagnosed based on partial CD34 positivity in many previous reports. On the other hand, the Antoni B area of some schwannomas was reported to be positive for CD34. Therefore, the definition of a hybrid tumor has not been clear. The objective of this study was to determine whether only CD34 positive findings in schwannomas could be used to define a hybrid tumor. In the analysis of our patient with schwannomatosis caused by a novel LZTR1 germline mutation, part of the tumor had CD34 positive hypocellular regions. These regions contained no thin, wavy, nuclei, indicating an Antoni B area. Laser microdissection was used to investigate the genetic background and differences in molecular mechanisms between CD34 positive and CD34 negative regions. All mutations identified in CD34 positive regions were also found in CD34 negative regions. Our data could not clear the genetic background of Antoni B which was CD34 positive area. We then reviewed the pathologies of 66 sporadic schwannomas. Histopathological examinations of all schwannomas revealed the absence of thin, wavy, nuclei and wavy collagen bands, and no hybrid tumors were found in any of the cases. Ten of 66 patients were randomly selected for CD34 immunostaining and positivity was found in all cases. Our data suggest that it is difficult to distinguish schwannomas by staining for CD34 alone, as Antoni B areas can also be positive for CD34. Therefore, CD34 staining alone should not be used to diagnose hybrid tumors in patients with schwannomas., (© 2024 Japanese Dermatological Association.)

Published
2024
Full Text
View/download PDF

46. SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma.

Author

Akashi H, Yachida N, Ueda H, Yamaguchi M, Yamawaki K, Tamura R, Suda K, Ishiguro T, Adachi S, Nagase Y, Ueda Y, Ueda M, Abiko K, Kagabu M, Baba T, Nakaoka H, Enomoto T, Murai J, and Yoshihara K

Subjects
Humans, Female, BRCA1 Protein genetics, Retrospective Studies, BRCA2 Protein genetics, Biomarkers, Tumor genetics, Biomarkers, Tumor analysis, Nuclear Proteins genetics, Ovarian Neoplasms drug therapy, Ovarian Neoplasms genetics, Ovarian Neoplasms pathology, Adenocarcinoma, Clear Cell drug therapy, Adenocarcinoma, Clear Cell genetics
Abstract

BRCA1/2 mutations are robust biomarkers for platinum-based chemotherapy in epithelial ovarian cancers. However, BRCA1/2 mutations in clear cell ovarian carcinoma (CCC) are less frequent compared with high-grade serous ovarian cancer (HGSC). The discovery of biomarkers that can be applied to CCC is an unmet need in chemotherapy. Schlafen 11 (SLFN11) has attracted attention as a novel sensitizer for DNA-damaging agents including platinum. In this study, we investigated the utility of SLFN11 in HGSC and CCC for platinum-based chemotherapy. SLFN11 expression was analyzed retrospectively by IHC across 326 ovarian cancer samples. The clinicopathologic significance of SLFN11 expression was analyzed across 57 advanced HGSC as a discovery set, 96 advanced HGSC as a validation set, and 57 advanced CCC cases, all of whom received platinum-based chemotherapy. BRCA1/2 mutation was analyzed using targeted-gene sequencing. In the HGSC cohort, the SLFN11-positive and BRCA mutation group showed significantly longer whereas the SLFN11-negative and BRCA wild-type group showed significantly shorter progression-free survival and overall survival. Moreover, SLFN11-positive HGSC shrunk significantly better than SLFN11-negative HGSC after neoadjuvant chemotherapy. Comparable results were obtained with CCC but without consideration of BRCA1/2 mutation due to a small population. Multivariate analysis identified SLFN11 as an independent factor for better survival in HGSC and CCC. The SLFN11-dependent sensitivity to platinum and PARP inhibitors were validated with genetically modified non-HGSC ovarian cancer cell lines. Our study reveals that SLFN11 predicts platinum sensitivity in HGSC and CCC independently of BRCA1/2 mutation status, indicating that SLFN11 assessment can guide treatment selection in HGSC and CCC., (©2023 American Association for Cancer Research.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results